Prior Authorization Is Not a Paperwork Problem. It Is a Clinical One.

Every nurse who has worked an inpatient floor knows the moment. The attending has ordered a medication or a procedure. The patient needs it. And then the floor goes quiet for a few hours while someone upstream, usually a utilization reviewer working from a checklist, decides whether the order is appropriate.

Prior authorization gets framed as an administrative burden, a billing friction point, a thing that frustrates physicians and delays discharges. All of that is true. But framing it as administrative obscures what is actually happening clinically when a coverage decision interrupts a care plan.

The first clinical consequence is delay. In cardiology, oncology, and psychiatry especially, the window between diagnosis and treatment initiation matters. Studies examining authorization-related delays in cancer care have found associations between delayed systemic therapy starts and worse outcomes, particularly in fast-moving malignancies. The delay is not neutral. It is a clinical interval during which the patient's condition does not pause.

The second consequence is substitution. When a requested treatment is denied, clinicians do not always get a peer-to-peer review that results in approval. Often, they pivot to a covered alternative. Sometimes the covered alternative is clinically equivalent. Sometimes it is not. The patient with a documented intolerance to a first-line agent, or whose prior treatment history makes the covered drug a poor fit, absorbs the mismatch. Clinicians call this "fail-first" or step therapy, and while step therapy protocols have legitimate rationale in some contexts, applying them uniformly regardless of individual patient history is not evidence-based care. It is coverage-based care.

The third consequence is abandonment. This one is underreported. Research on specialty medication access consistently finds that a meaningful share of patients, estimates range from roughly one in four to one in three depending on the drug class and patient population, do not complete the authorization process or fill the prescription even after approval. The process itself functions as a filter. Patients with lower health literacy, patients who are working multiple jobs, patients without a care coordinator in their corner, are more likely to fall out. Authorization processes designed to reduce low-value utilization can end up reducing utilization period, including high-value utilization among the people least equipped to fight for it.

The physicians most vocal about this issue are not, in the main, demanding that payers write blank checks. Most clinicians understand the concept of stewardship. What they are describing is a structural mismatch: authorization criteria written at the population level, applied to individual patients by reviewers who in many cases are not trained in the specialty and have not examined the patient. A health plan's medical director reviewing an oncology case may be a physician, but specialization matters. An internist reviewing a request for a monoclonal antibody in a rare autoimmune condition is not the same as a rheumatologist who manages that condition weekly.

There is also a documentation burden that falls disproportionately on primary care and small practices without dedicated prior-auth staff. The unintended consequence is that patients of solo practitioners and federally qualified health centers face higher denial and abandonment rates than patients of large academic medical centers with authorization specialists on staff. Access stratifies along lines that have nothing to do with clinical need.

None of this means prior authorization has no legitimate function. Utilization management exists because overtreatment is a real harm. But a tool that started as a check on outlier prescribing has expanded into a default requirement across drug classes, procedures, and imaging at a scale that now touches routine care. At that scale, the clinical costs deserve the same scrutiny the cost-savings are given.